ustekinumab-hmny | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

387 results for “ustekinumab-hmny”

Trials

View all 211 →

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

500 participants · First posted Apr 11, 2017

Ustekinumab Real World Evidence Study

601 participants · First posted Aug 5, 2026

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects

201 participants · First posted Feb 26, 2021

Drugs

View all 22 →

Ustekinumab biosimilar

Ustekinumab(Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi, Absimky, Imuldosa, Yesintek, Qoyvolma, Usymro, Usrenty, Usgena)

Manufacturer: Johnson & Johnson (Janssen Pharmaceutical Companies)

Conditions: Severe Plaque psoriasis, Ulcerative Colitis, Active Severe +5 more

Rx

USTEKINUMAB-AEKN

News

View all 154 →

Hikma Launches First US Biosimilar STARJEMZA, Seventh Ustekinumab Alternative to Enter Market

EMA Approves First Ustekinumab Biosimilar, Uzpruvo, for Inflammatory Conditions

FDA Approves Alvotech/Teva's Ustekinumab Biosimilar, SELARSDI

Page 1 of 39